17 Nov 08 Bone Marrow Toxicity In Advanced Lung Cancer May Be Reduced By Proton Therapy And Concurrent Chemotherapy
Patients treated for locally advanced non-small cell lung cancer who receive chemotherapy and proton beam therapy have fewer instances of bone marrow toxicity than patients who receive the standard treatment of intensity-modulated radiation (IMRT) and concurrent chemotherapy, according to researchers from The University of Texas M. D. Anderson Cancer Center.
(more…)
Tags: Anderson Cancer Center, Bone Cancer, Bone Marrow Toxicity, Cancer Chemotherapy, Cancer Therapy, Cell Lung Cancer, Chemotherapy, Chemotherapy Patients, Imrt, Instances, Intensity Modulated Radiation, Lung Cancer, M D Anderson, M D Anderson Cancer Center, Non Small Cell Lung Cancer, Proton Beam Therapy, Proton Therapy, Small Cell Lung Cancer, University Of Texas, University Of Texas M D Anderson Cancer Center
11 Nov 08 Despite Promising Laboratory Data Bone Cancer Treatment Ineffective
Ewing sarcoma is the second most common type of primary bone cancer seen in children and young adults. Patients with relapsed or refractory Ewing sarcoma have a poor outcome with conventional therapies. Cytarabine decreases the levels of a certain key protein in Ewing sarcoma cells and has demonstrated preclinical activity against Ewing sarcoma cell lines in the laboratory. Treatment of Ewing sarcoma that relapses is difficult.
(more…)
Tags: Bone Cancer, Cancer Treatment, Cells, Conventional Therapies, Cytarabine, Ewing Sarcoma, Laboratory Data, Poor Outcome, Protein, Young Adults
11 Nov 08 Despite Promising Laboratory Data Bone Cancer Treatment Ineffective
Ewing sarcoma is the second most common type of primary bone cancer seen in children and young adults. Patients with relapsed or refractory Ewing sarcoma have a poor outcome with conventional therapies. Cytarabine decreases the levels of a certain key protein in Ewing sarcoma cells and has demonstrated preclinical activity against Ewing sarcoma cell lines in the laboratory. Treatment of Ewing sarcoma that relapses is difficult.
(more…)
Tags: Bone Cancer, Cancer Treatment, Cells, Conventional Therapies, Cytarabine, Ewing Sarcoma, Laboratory Data, Poor Outcome, Protein, Young Adults
18 Sep 08 Drug Can Slow Bone Loss in Prostate Cancer Patients (HealthDay)
HealthDay - THURSDAY, Sept. 18 (HealthDay News) — Men receiving
hormone-deprivation therapy for advanced but localized prostate cancer can
develop bone loss as a side effect of the treatment.
(more…)
Tags: Advanced Cancer, Bone Cancer, Bone Loss, Cancer Bone, Healthday, Prostate, Prostate Cancer, Prostate Cancer Patients
18 Sep 08 Drug Can Slow Bone Loss in Prostate Cancer Patients (HealthDay)
HealthDay - THURSDAY, Sept. 18 (HealthDay News) — Men receiving
hormone-deprivation therapy for advanced but localized prostate cancer can
develop bone loss as a side effect of the treatment.
(more…)
Tags: Advanced Cancer, Bone Cancer, Bone Loss, Cancer Bone, Healthday, Prostate, Prostate Cancer, Prostate Cancer Patients
18 Sep 08 Drug Can Slow Bone Loss in Prostate Cancer Patients (HealthDay)
HealthDay - THURSDAY, Sept. 18 (HealthDay News) — Men receiving
hormone-deprivation therapy for advanced but localized prostate cancer can
develop bone loss as a side effect of the treatment.
(more…)
Tags: Advanced Cancer, Bone Cancer, Bone Loss, Cancer Bone, Healthday, Prostate, Prostate Cancer, Prostate Cancer Patients
18 Sep 08 Drug Can Slow Bone Loss in Prostate Cancer Patients (HealthDay)
HealthDay - THURSDAY, Sept. 18 (HealthDay News) — Men receiving
hormone-deprivation therapy for advanced but localized prostate cancer can
develop bone loss as a side effect of the treatment.
(more…)
Tags: Advanced Cancer, Bone Cancer, Bone Loss, Cancer Bone, Healthday, Prostate, Prostate Cancer, Prostate Cancer Patients
17 Sep 08 Drug Stops Bone Loss From Breast Cancer Chemo (HealthDay)
HealthDay - THURSDAY, Aug. 21 (HealthDay News) — Zometa (zoledronic acid)
prevented bone loss at 12 months in premenopausal women undergoing
chemotherapy after they had surgery for early stage breast cancer, a new
study found.
(more…)
Tags: 12 Months, Bone Cancer, Bone Loss, Breast Cancer, Breast Cancer Chemo, Chemotherapy, Healthday, Premenopausal Women, Stage Breast Cancer, Zoledronic Acid, Zometa
17 Sep 08 Osteo Drug Stops Bone Loss From Breast Cancer Chemo (HealthDay)
HealthDay - THURSDAY, Aug. 21 (HealthDay News) — The osteoporosis drug Zometa
(zoledronic acid) prevented bone loss at 12 months in premenopausal women
undergoing chemotherapy after they had surgery for early stage breast
cancer, a new study found.
(more…)
Tags: 12 Months, Bone Cancer, Bone Loss, Breast Cancer, Breast Cancer Chemo, Chemotherapy, Healthday, Osteoporosis, Osteoporosis Drug, Premenopausal Women, Stage Breast Cancer, Zoledronic Acid, Zometa
16 Sep 08 Drug Stops Bone Loss From Breast Cancer Chemo (HealthDay)
HealthDay - THURSDAY, Aug. 21 (HealthDay News) — Zometa (zoledronic acid)
prevented bone loss at 12 months in premenopausal women undergoing
chemotherapy after they had surgery for early stage breast cancer, a new
study found.
(more…)
Tags: 12 Months, Bone Cancer, Bone Loss, Breast Cancer, Breast Cancer Chemo, Chemotherapy, Healthday, Premenopausal Women, Stage Breast Cancer, Zoledronic Acid, Zometa
16 Sep 08 Osteo Drug Stops Bone Loss From Breast Cancer Chemo (HealthDay)
HealthDay - THURSDAY, Aug. 21 (HealthDay News) — The osteoporosis drug Zometa
(zoledronic acid) prevented bone loss at 12 months in premenopausal women
undergoing chemotherapy after they had surgery for early stage breast
cancer, a new study found.
(more…)
Tags: 12 Months, Bone Cancer, Bone Loss, Breast Cancer, Breast Cancer Chemo, Chemotherapy, Healthday, Osteoporosis, Osteoporosis Drug, Premenopausal Women, Stage Breast Cancer, Zoledronic Acid, Zometa
